$SRPT

Sarepta Therapeutics reported Q3 2026 net product revenues of $323.8M, with $240.3M from PMO and $83.5M from ELEVIDYS. The company raised its revenue guidance and lowered expense guidance. It expects multiple ascending dose data for SRP-1003 and SRP-1001 by year-end, preparing for Phase 3 development. Sarepta also presented new clinical data supporting ELEVIDYS's benefit-risk profile.

Baird reduced its price target for Sarepta Therapeutics (SRPT) to $18.00 from $20.00, citing concerns over near-term growth of its Elevidys product. The company's Q3 revenue beat expectations but declined 20% year-over-year. SRPT reported adjusted earnings of $0.13 per share, exceeding estimates, but stock faced pressure due to weaker product sales and higher costs.

Sarepta Therapeutics Inc. (SRPT) reported a Q3 loss of $28.5 million, or 27 cents per share, missing analyst expectations of 37 cents per share. Adjusted earnings were 13 cents per share. Revenue of $381.4 million exceeded forecasts of $348.5 million, according to Zacks Investment Research.

Sarepta Therapeutics, Inc. (SRPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments – Upcoming multiple ascending dose data from SRP-1003 in DM1 and SRP-1001 in FSHD expected by year end; Company is actively preparing for Phase 3 development in both

The FDA issued draft guidance to accelerate personalized gene therapies for rare diseases, offering regulatory clarity for developers. The move aims to streamline approval processes for tailored treatments, benefiting companies like Ultragenyx Pharmaceutical (RARE).

H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a $5.00 price target, citing Phase 3 trial concerns and no change in approval probability. SRPT's stock is down 20% YTD but has a Fair Value of $21.05. Q2 2026 earnings beat expectations, but sales declined due to reduced demand for ELEVIDYS. Analysts have mixed opinions, with Jefferies and Mizuho maintaining Buy/Outperform ratings and higher targets.

Sarepta's ELEVIDYS showed improved motor function in older DMD patients over 2 years. Dompé began a phase 2 trial for intranasal NGF in cerebral palsy. A roundtable discussed precision medicine in MS.

Sarepta Therapeutics reported preclinical data for SRP-1003, showing up to 80% DMPK knockdown and MBNL mis-splicing correction. The drug is in a Phase 1/2 trial, with results expected later this year.

Sarepta Therapeutics (SRPT) presented new ELEVIDYS gene therapy data, extending evidence to older Duchenne patients. The stock has fallen 22.22% in 30 days, trading at $17.50, while the consensus fair value is $21.73. The company's Duchenne portfolio has 75% gross margins and $86M non-GAAP operating income, supporting pipeline work.

Genmab and AbbVie's Epkinly showed promising results in a Phase 3 study, reducing disease progression or death risk by 51% in lymphoma patients. IntraBio was acquired by Shionogi for $2 billion, expanding Aqneursa's approvals. Novartis invested up to $7.8 billion in Abogen Biosciences. Eli Lilly and CSL also announced significant biopharma deals. Sarepta Therapeutics presented positive Elevidys data, with upcoming catalysts for its treatments.